# OnCo record kt-200 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/kt-200/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "kt-200" ;
  schema:name "KT-200"@en ;
  schema:description "KT-200 is an experimental molecular glue degrader from Kymera Therapeutics, in preclinical development for CCNE1-amplified or over-expressed cancers and breast cancer."@en ;
  schema:url <https://onco.cc/drugs/kt-200/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.biospace.com/press-releases/kymera-therapeutics-announces-gilead-sciences-option-exercise-to-license-kt-200-oral-cdk2-molecular-glue-degrader-development-candidate>, <https://www.biospace.com/press-releases/kymera-therapeutics-announces-gilead-sciences-option-exercise-to-license-kt-200-oral-cdk2-molecular-glue-degrader-development-candidate>, <https://www.sec.gov/Archives/edgar/data/1815442/000119312526436965/kymr-ex99_1.htm> ;
  onco:status "preclinical" ;
  onco:tag "pipeline" ;
  onco:modality "Molecular glue degrader (oral)" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:targets <https://onco.cc/targets/cdk2/> ;
  onco:companies <https://onco.cc/companies/kymera/>, <https://onco.cc/companies/gilead/> .